Patricia Allen - Deciphera Pharmaceuticals Independent Director
| DCPH Stock | USD 25.36 0.09 0.36% |
Director
Ms. Patricia L. Allen is an Independent Director of the Company. Ms. Allen has served as Chief Financial Officer of Zafgen, Inc. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte Touche, LLP since 2016.
| Age | 56 |
| Tenure | 8 years |
| Address | 200 Smith Street, Waltham, MA, United States, 02451 |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5629) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.43. The current Return On Capital Employed is estimated to decrease to -0.59. As of now, Deciphera Pharmaceuticals' Fixed Asset Turnover is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Asset Turnover is estimated to increase to 0.36, while Total Assets are projected to decrease to under 393.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Edward Owens | Ironwood Pharmaceuticals | 71 | |
| Frederick Hudson | Supernus Pharmaceuticals | 72 | |
| Floyd Petersen | Amphastar P | 74 | |
| Amy Schulman | Ironwood Pharmaceuticals | 57 | |
| John Freund | Collegium Pharmaceutical | 64 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| David Anstice | Alkermes Plc | 69 | |
| Richard Koo | Amphastar P | 77 | |
| Garen Bohlin | Collegium Pharmaceutical | 70 | |
| David Hirsch | Collegium Pharmaceutical | 47 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Benoit Assche | Avadel Pharmaceuticals PLC | 70 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Christophe Navarre | Avadel Pharmaceuticals PLC | ||
| Meredith Kaya | Ironwood Pharmaceuticals | N/A | |
| Fred Holubow | ANI Pharmaceuticals | 77 | |
| Andrew Dreyfus | Ironwood Pharmaceuticals | 59 | |
| Jon Duane | Ironwood Pharmaceuticals | 59 | |
| Patrick Heron | Collegium Pharmaceutical | 44 | |
| Thomas Haughey | ANI Pharmaceuticals | 54 | |
| Catherine Moukheibir | Ironwood Pharmaceuticals | 58 | |
Management Performance
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.28 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Ruddy, VP Officer | ||
| John Martin, Independent Director | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Patricia Allen, Independent Director | ||
| Thomas Kelly, CFO | ||
| Susan Kelley, Director | ||
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Liam Ratcliffe, Independent Director | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Kevin Brodbeck, Senior Officer | ||
| Christopher Morl, Chief Business Officer | ||
| Oliver Rosen, Chief Medical Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Michael Taylor, President CEO, Director | ||
| Melissa Forst, IR Contact Officer | ||
| James Bristol, Independent Director | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Edward Benz, Independent Director | ||
| Thomas JD, CFO VP | ||
| Dennis Walsh, Independent Director | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory | ||
| Michael Ross, Independent Director |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 1.77 B | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 30.02 % | ||||
| Shares Owned By Institutions | 72.29 % | ||||
| Number Of Shares Shorted | 5.75 M | ||||
| Price To Earning | (6.78) X |
Pair Trading with Deciphera Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Deciphera Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Deciphera Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Deciphera Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Deciphera Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Deciphera Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Deciphera Pharmaceuticals LLC to buy it.
The correlation of Deciphera Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Deciphera Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Deciphera Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Deciphera Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Deciphera Pharmaceuticals LLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Deciphera Stock analysis
When running Deciphera Pharmaceuticals' price analysis, check to measure Deciphera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Deciphera Pharmaceuticals is operating at the current time. Most of Deciphera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Deciphera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Deciphera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Deciphera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Deciphera Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.29) | Revenue Per Share 1.92 | Quarterly Revenue Growth 0.329 | Return On Assets (0.28) | Return On Equity (0.56) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.